The Effect of Rebamipide for Non-steroidal Anti-inflammatory Drugs (NSAID) - Induced Small-intestinal Injuries
- Registration Number
- NCT00862628
- Lead Sponsor
- Nagoya University
- Brief Summary
The purpose of this study is to evaluate the efficacy of rebamipide for NSAID-induced small-intestinal injuries.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Written informed consent
- 20 to 85 years of age
- RA, OA, or low back pain
- No change of drugs before 3 months
- Under 5 mg of corticosteroid use
- CRP < 1mg/dl
- Small-intestinal mucosal injuries more than one
- Hemoglobin level is below normal range
Exclusion Criteria
- Known or suspected small-bowel disease, including Crohn's disease and seronegative arthritis
- Prostaglandins, metronidazole or salazosulfapyridine
- Can not swallow
- Eith pacemaker
- After gastrointestinal operation
- Serious concomitant cardiovascular, endocrine, gastrointestinal(including symptoms of ileus), neurologic, psychiatric, renal, or respiratory disease.
- Taking rebamipide before one week
- Any other conditions that the investigator feels would interfere with data interpretation or create under risk.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Rebamipide Rebamipide -
- Primary Outcome Measures
Name Time Method The number of mucosal breaks 4 and 8 weeks after treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Gastroenterology, Nagoya University Graduate School of Medicine
🇯🇵Nagoya, Aichi Prefecture, Japan